Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

2024-514357-29-00 Protocol GCT1056-01 Human pharmacology (Phase I) - First administration to humans Ended

Start 4 Nov 2022 · End 23 Oct 2025 · Status Ended · 1 EU/EEA countries · 5 sites · Protocol GCT1056-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 26
Countries 1
Sites 5

Advanced solid tumors

Key facts

Sponsor
Genmab A/S
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
4 Nov 2022 → 23 Oct 2025
Decision date (initial)
2024-10-02
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-514357-29-00
EudraCT number
2022-001003-40
ClinicalTrials.gov
NCT05586321

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065147 Malignant solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Genmab A/S

Sponsor organisation
Genmab A/S
Address
Carl Jacobsens Vej 30
City
Valby
Postcode
2500
Country
Denmark

Scientific contact point

Organisation
Genmab A/S
Contact name
Genmab Trial Information

Public contact point

Organisation
Genmab A/S
Contact name
Genmab Trial Information

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 18 5
Rest of world
Georgia, Moldova, Republic of
8

Investigational sites

Spain

5 sites · Ended
Hospital Universitari Vall D Hebron
Oncology Department, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Research Facility, Avenida De Los Reyes Catolicos 2, 28040, Madrid
MD Anderson Cancer Center
Research Facility, Calle De Arturo Soria Nº 270, 28033, Madrid
Clinica Universidad De Navarra
Research Facility, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2022-11-04 2025-10-23 2022-11-22 2023-11-02

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-25 Spain Acceptable
2024-10-02
2024-10-02